Investment
Features
FeesSafety
Academy
More
Pluang+

Compare BioNTech SE - ADR (BNTX) vs DraftKings Inc (DKNG) Price & Performance

BioNTech SE - ADRTrade
DraftKings IncTrade

Price performance (Past 24H)

Key statistics

BioNTech SE - ADR vs DraftKings Inc — how do they compare? BioNTech SE - ADR trades at $93.19 (market cap $23.31B), while DraftKings Inc trades at $25.69 (market cap $12.58B). The key difference: BioNTech SE - ADR is the larger of the two by market cap. Which is the better fit depends on your goals.

BNTXDKNG
Market Cap
$23.31B$12.58B
Sector
HealthConsumer Cyclical
52-Week High
$119.34$48.23
52-Week Low
$83.89$20.72
Enterprise Value
$6.60B$13.51B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

BioNTech SE - ADR

BioNTech (BNTX) trades at $93.27, up 0.51% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported Q2 2026 revenue of $106 million, missing expectations, and lowered its full-year sales outlook due to weak COVID-19 vaccine demand. Despite negative net income margins and cash outflows, BNTX maintains a strong cash position of $16.78 billion and is advancing its oncology pipeline with 14 pivotal clinical trials.

The outlook is mixed: analyst consensus is strongly bullish with a $121 price target, but declining COVID revenue and ongoing losses pose significant risks. Investment opportunity hinges on successful pipeline development, while near-term headwinds from vaccine demand softness and leadership transition require careful monitoring.

DraftKings Inc

DraftKings (DKNG) trades at $25.65, up 5.69% on the day, with a bullish technical signal and strong analyst support. The company reported mixed Q2 2026 results, missing earnings estimates but showing robust prediction market growth. Revenue reached $6.05B in 2025, with positive net income of $3.71M, marking a significant turnaround from prior losses. Cash flow from operations improved to $662.86M, though net cash flow turned negative in 2026 projections.

The outlook is cautiously optimistic, driven by prediction market expansion and cost management, but risks include intense competition and promotional pressures. With a consensus price target of $34.00 and 73% buy ratings, upside potential exists if execution continues. Investors should weigh growth prospects against valuation premiums and earnings volatility.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About BioNTech SE - ADR

BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.

Read more on BNTX

About DraftKings Inc

DraftKings Inc is a digital sports entertainment and gaming company. The company provides users with daily fantasy sports (DFS), sports betting, and iGaming opportunities and is also involved in the design & development of sports betting and casino gaming platform software for online and retail sportsbook and casino gaming products. It operates in two segments: Business-to-consumer(B2C) and Business-to-Business(B2B), of which the vast majority of its revenue comes from the B2C segment. Geographically, it derives most of its revenue from the United States.

Read more on DKNG